Bio Solution Co Ltd

The company's capital structure is characterized by a debt-to-equity ratio of 0.94, indicating a relatively balanced mix of debt and equity financing. Despite a current ratio of 0.57, which suggests potential liquidity constraints, the firm maintains a cash and equivalents balance of 11,882,795,470 KRW. However, the negative net cash position after subtracting total debt raises concerns about short-term liquidity.

Profitability metrics show a return on equity (ROE) of 0.85% and a return on assets (ROA) of 0.4%, both of which are below the industry median for pharmaceutical firms. The operating margin is 3.5%, and the net profit margin is 1.8%, indicating that the company is generating modest returns relative to its revenue.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks, particularly in the South Korean healthcare sector.

Looking ahead, the company is expected to see a 32% increase in revenue in the current fiscal year, based on analyst estimates of 20,000,000,000 KRW. However, the operating income is projected to decline, with a negative EBIT estimate of -1,000,000,000 KRW. This suggests that while top-line growth is anticipated, profitability may come under pressure.

The risk assessment highlights a medium liquidity risk and a low dilution risk. The firm has not issued additional shares recently, and the diluted share count remains unchanged at 24,172,444 shares. However, the negative operating cash flow of -1,311,613,030 KRW and the capital expenditure of -731,519,350 KRW indicate that the company is investing in growth while managing cash outflows.

Recent filings and transcripts do not indicate any major strategic shifts or regulatory challenges. The company continues to focus on its core therapeutic areas and is in the process of expanding its product pipeline.